BRAF inhibitor-induced panniculitis appearance on 18F-FDG PET/CT

Clinical Nuclear Medicine

Volumn 41, Issue 3, 2016, Pages e149-e151

  Broski, Stephen M ^a   Moran, Erin K ^a   Glazebrook, Katrina N ^a   Nathan, Mark A ^a  

^a MAYO CLINIC   (United States)

Author keywords

BRAF; FDG; Panniculitis; PET CT

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; TRAMETINIB; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE; VEMURAFENIB;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG INDUCED DISEASE; ERYTHEMA; HUMAN; MALE; MEDICAL HISTORY; MENINGEAL METASTASIS; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANNICULITIS; PRIMARY TUMOR; SKIN NODULE; SPINE METASTASIS; SYSTEMIC THERAPY; WIDE EXCISION; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; GENETICS; MELANOMA; METASTASIS; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; FLUORODEOXYGLUCOSE F18; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MULTIMODAL IMAGING; NEOPLASM METASTASIS; OXIMES; PANNICULITIS; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84944345258     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001027     Document Type: Article

References (10)

1. Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72:221-236; quiz 237-228.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
4. Choy B, Chou S, Anforth R, et al. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36:493-497.
5. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22:399-401.
6. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013; 40:667-669.
7. Sinha R, Edmonds K, Newton-Bishop J, et al. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol. 2013;31:e320-e321.
8. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148:357-361.
9. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, et al. Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity. Dermatol Online J. 2013;19:16.
10. Abramson RG, Abramson VG, Chan E, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013;200:475-483.